Generate Biomedicines, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GENB | 1873.HK | DNA | PBLS | O15.F | PGEN | |
|---|---|---|---|---|---|---|
| Market cap | 1.82B | 2.80B | 784.51M | 3.75B | 2.54B | 1.81B |
| P/E (TTM) | — | 16.9 | — | — | — | — |
| Forward P/E | -6.2 | 6.2 | -4.0 | -13.9 | — | -23.0 |
| Price/book | 4.0 | 0.6 | 1.8 | 3.6 | 5.2 | 85.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +9.49% | −43.17% | −7.16% | −3.92% | −22.42% | +29.08% |
| Today | +2.24% | +5.04% | +8.27% | +3.79% | 0.00% | −3.71% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All GENB news ›Introducing SynthID Bio
딥마인드가 SynthID Bio를 공개했습니다. AI가 생성한 단백질 서열에 워터마크를 심으면서도 생물학적 기능을 유지하는 개념 증명입니다. 저는 이 발표에서 두 가지가 흥미로웠습니다. 첫째, 서열 수준의 출처 표시 문제가 본격적으로 다뤄지기 시작했다는 점. 둘째, 그와 동시에 구조 수준의 이해는 여전히 사람의 몫이라는 점입니다. 워터마크가 "이 서열은 AI가 만들었다"를 알려줘도, 그 단백질이 실제로 어떤 포켓을 갖고 어떤…
Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI
/PRNewswire/ -- Generate:Biomedicines ("Generate") today announced it plans to initiate two global Phase 3 clinical trials, SOLAIRIA-1 and SOLAIRIA-2,... SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with…
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Press release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases The collaboration is intended to accelerate the…
Generate Biomedicines, Zealand Pharma enter protein therapeutics pact
Generate Biomedicines (GENB) announced a multi-target strategic collaboration with Zealand Pharma (ZLDPF). Under the collaboration, the companie... Generate Biomedicines, Zealand Pharma enter protein therapeutics pact Generate Biomedicines…
Zealand taps Generate’s AI for obesity proteins in nearly $1.2b deal
Zealand Pharma has been a peptide company for more than 25 years, and now the Copenhagen outfit is asking an AI specialist to help it branch into proteins. Peptides and proteins are made of the same basic building blocks, amino acids,…
More from 1 other outlet
Financial Comparison: Generate Biomedicines (NASDAQ:GENB) versus Ascendis Pharma A/S (NASDAQ:ASND)
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) and Generate Biomedicines (NASDAQ:GENB – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their…
Banque Pictet & Cie SA Buys New Position in Generate Biomedicines Inc $GENB
Posted by Defense World Staff on Oct 17th, 2026 Shares of Generate Biomedicines stock opened at $12.09 on Friday. Generate Biomedicines Inc has a fifty-two week low of $11.00 and a fifty-two week high of $22.67. The company’s 50 day moving…
Generate Biomedicines Signs Deal Worth Up to $1.2 Billion with Zealand Pharma for AI-Designed Protein Drugs
Generate, Zealand Sign $1.2B AI Drug Deal Voice of Healthcare
Zealand Pharma CEO hails AI protein deal with Generate Biomedicines
Senior Manager, Finance Business Partner Head of Medical Affairs International Markets Chef for Kvalitet og Compliance Manager, Corporate Affairs, Denmark & Norway Associate Market Access Director – International Markets Senior Drug…
Generate Biomedicines, Zealand Pharma Join Hands in USD 1.2 Billion AI-Driven Obesity Drug Deal
Bengaluru: Danish obesity-drug developer Zealand Pharma has partnered with US biotechnology company Generate Biomedicines to develop protein-based treatments for obesity and other metabolic diseases using AI, in a deal worth up to USD 1.2…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- defenseworld.net2
- markets.businessinsider.com2
- european-biotechnology.com1
- globenewswire.com1
- hoodline.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 14 articles, not a forecast.